Clinical Trials

The API Innovation Center, Apertus Pharmaceuticals Bring API Production of Critical Generic Cancer Drug to U.S. Soil

Retrieved on: 
Tuesday, April 9, 2024
Manufacturing, Retail, White House, Federal Government, Pharmaceutical, Research, Oncology, Supply Chain Management, Foundation, Science, Philanthropy, Public Policy, Government, Clinical Trials, General Health, Biotechnology, Health, Healthcare Reform, Health Technology, Chemicals, Plastics, Growth, Medication, Environment, Partnership, Lomustine, Patient, Pharmacy, Economic development, Cancer, Glioblastoma, Investment, API, Soil, Pharmaceutical industry

“Apertus Pharmaceuticals is proud to be selected as the contract manufacturer for lomustine,” said David Gindelberger, president and chief scientific officer of Apertus Pharmaceuticals.

Key Points: 
  • “Apertus Pharmaceuticals is proud to be selected as the contract manufacturer for lomustine,” said David Gindelberger, president and chief scientific officer of Apertus Pharmaceuticals.
  • "The St. Louis region is at the forefront of emerging technologies and API production,” said Sen. Brian Williams, D- St. Louis.
  • In 2023, the API Innovation Center was awarded $9.5 million from the Missouri Technology Corporation’s Advanced Manufacturing Resiliency Grant Program.
  • With this support, the API Innovation Center is investing in building a regional hub for drug advanced manufacturing, establishing Missouri as a leader in domestic API production to secure the U.S. essential drug supply chain.

S2 Genomics Announces Groundbreaking Single Cell FFPE Sample Prep Isolation Product

Retrieved on: 
Tuesday, April 9, 2024
Chemicals, Plastics, Electronic Design Automation, Manufacturing, Technology, Stem Cells, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Other Manufacturing, Other Technology, Biotechnology, Science, Research, Health, Genomics, Tissue, RNA, The central science, Antibiotics

S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The new FFPE sample prep isolation system is designed to isolate nuclei from FFPE tissue slices, enabling single-nucleus RNA sequencing (snRNA-Seq) for FFPE samples.
  • Jonathan Schimmel, President and CEO of S2 Genomics, expressed his enthusiasm for the new product: “The FFPE sample prep isolation system is a testament to our commitment to continuing innovation and excellence in the field of single cell genomics.
  • For more information about the FFPE sample prep isolation system and other S2 Genomics products, please visit us at s2genomics.com or connect with us on LinkedIn or Twitter .

Julie Blasingim Promoted to Chief Executive Officer of Univo IRB

Retrieved on: 
Tuesday, April 9, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Growth, Independent, Education, Patient, Multimedia, Human

Univo IRB , a next generation institutional review board (IRB) backed by QHP Capital, today announced Julie Blasingim has been promoted to CEO by Univo’s board of directors.

Key Points: 
  • Univo IRB , a next generation institutional review board (IRB) backed by QHP Capital, today announced Julie Blasingim has been promoted to CEO by Univo’s board of directors.
  • As CEO, Blasingim will drive Univo IRB’s strategic growth and innovation, bringing a modern iteration of IRB solutions to unify patients and research, and support today’s clinical trials.
  • View the full release here: https://www.businesswire.com/news/home/20240409809970/en/
    Julie Blasingim has been named CEO of Univo IRB by QHP Capital.
  • With Julie’s leadership coming together along with her seasoned executive team including, Cyrus Gill, Executive IRB Chair, and Heather Fitzgerald, VP of Operations, Univo IRB is poised to continue making an impact on the research community.

Vertex to Announce First Quarter 2024 Financial Results on May 6

Retrieved on: 
Tuesday, April 9, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, International, Webcast, Vertex Pharmaceuticals, Vertex, VRTX

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.
  • The company will host a conference call and webcast at 4:30 p.m.
  • To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2024 Earnings Call.”
    The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section.
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Retrieved on: 
Tuesday, April 9, 2024
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Development, Risk, Diabetes, Ageing, Chronic obstructive pulmonary disease, Head, RSV, Senior, Asthma, Safety, Vaccine, Person

Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.

Key Points: 
  • Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.
  • However, no RSV vaccines have been approved for use in adults 18 to 59 years of age.
  • The MONeT study was initiated to address this significant unmet need by investigating the immunogenicity and safety of ABRYSVO in adults aged 18 to 59 at increased risk for RSV disease, such as those with asthma, diabetes, and chronic obstructive pulmonary disease.
  • “These encouraging results provide evidence that ABRYSVO can help protect adults with increased risk against RSV-associated illness,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer.

Bayer and Google Cloud to accelerate development of AI-powered healthcare applications for radiologists

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Practice Management, Software, Managed Care, General Health, Health Technology, Data Management, Clinical Trials, Cloud, Diagnosis, Google Cloud, Organization, Face, Medicine, Radiology, Drug discovery, Partnership, Ideation, Bias, BigQuery, Patient, Chronicle, Health care, Artificial intelligence, AI, Workload, Medical device

Bayer and Google Cloud today announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients.

Key Points: 
  • Bayer and Google Cloud today announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients.
  • As part of the collaboration, Bayer will further develop its innovation platform to accelerate the development and deployment of AI-powered healthcare applications with a clear focus on radiology, using Google Cloud’s technology, including its generative AI (gen AI) tools.
  • The platform is built on Google Cloud and uses tools like Vertex AI, BigQuery, Healthcare API and Chronicle.
  • Bayer and Google Cloud are also working together to transform patient care worldwide through responsible AI adoption.

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors

Retrieved on: 
Tuesday, April 9, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Arthralgia, Toxicity, Cell, NSCLC, RECIST, HNSCC, Patient, Diarrhea, Maculopapular rash, Lung cancer, Renal cell carcinoma, Injection site reaction, AACR, Nausea, Lymphocyte, Hypotension, RCC, Transaminase, Poster, Itch, CLS, Capillary leak syndrome, Fatigue, Vomiting, NK, Inc., Pharmaceutical industry

Synthekine Inc ., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, for the treatment of advanced solid tumors.

Key Points: 
  • Synthekine Inc ., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, for the treatment of advanced solid tumors.
  • The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
  • In the results presented, which included 47 patients treated in Phase 1a dose escalation, STK-012 monotherapy demonstrated a favorable safety, efficacy, pharmacokinetic and pharmacodynamic profile.
  • The poster, titled “Initial results from a Phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132),” will be presented today at AACR from 9 am to 12:30 pm PT.

Real Time Medical Systems Brings Post-acute Care Focus to NAACOS Spring 2024 Conference

Retrieved on: 
Tuesday, April 9, 2024
Software, Managed Care, General Health, Professional Services, Medical Devices, Technology, Infectious Diseases, Hospitals, Data Analytics, Clinical Trials, Nursing, Health, RN, ACO, Conference, Acos, KLAS, HITRUST, Real, Real-time, Patient, Policy, Senior, Circle, Length of stay, EHR, National Association, CMS

Real Time Medical Systems (Real Time), the industry leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its presence at the National Association of ACOs (NAACOS) Spring 2024 Conference on April 10-12, 2024.

Key Points: 
  • Real Time Medical Systems (Real Time), the industry leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its presence at the National Association of ACOs (NAACOS) Spring 2024 Conference on April 10-12, 2024.
  • Real Time joins CMS officials, ACO leaders, and policy insiders in Baltimore, MD, to demonstrate how providers can reduce hospital admissions/readmissions, minimize length of stay, and improve care coordination in the post-acute setting through Real Time’s interventional analytics platform.
  • The session takes place on Thursday, April 11, 2024, at 7:30am – 8:15am.
  • “I thoroughly enjoy speaking to the NAACOS audience,” states Phyllis Wojtusik, RN.

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, April 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Tobacco, Clinical Trials, Retail, Disease, Cardiovascular Research, Society, IND, Psychology, Therapy, Senior counsel, Population health, School, Dean (education), Partnership, Nicotine, Policy, Smoker, Behavior, NIH, Brown University, Trial of the century, University, SAB, Pharmacology, Homelessness, San Francisco General Hospital, UCSF, Public, Cancer, MD, Publication, Heated tobacco product, Hospital, Juul, FDA, Alpert Medical School, Pregnancy, Chair, Public health, University of Kansas, Cardiology, CTA, Mortality, Louisiana State University, Doctor of Philosophy, MHRA, Smoking, Toxicology, Division, Brown, Social science, Pharmaceutical industry

“We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.

Key Points: 
  • “We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.
  • Last fall, QN-01 demonstrated a superior pharmacokinetic profile compared to existing nicotine replacement therapies in our first-in-human Phase 1 clinical trial.
  • We plan to submit our IND and CTA to the regulatory bodies and look forward to commencing our Phase 1/2 clinical study this year.
  • He also served a three-year term on the Board of the Society for Research on Nicotine and Tobacco.

IGC Pharma Adds Advisor in Artificial Intelligence

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Other Technology, Research, Artificial Intelligence, Science, Clinical Trials, Diagnosis, Agitation, Biomedicine, Mathematics, Universidad, Algorithm, Biomedical engineering, Paris Dauphine University, Risk, Patient, Artificial intelligence, AI, University, Deep learning, Universidad de los Andes, Computer vision, IGC, GxP, Dementia, Medical device

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.
  • This will help IGC Pharma identify individuals who are most likely to respond to treatment and accelerate the delivery of treatments to patients.
  • Pablo Arbeláez is a distinguished researcher with over 20 years of experience in Computer Vision and Artificial Intelligence.
  • Ram Mukunda, CEO of IGC Pharma, stated, "We welcome Dr. Pablo Arbelaez to our team of Senior Advisors.